Patents by Inventor Hisako Muramatsu

Hisako Muramatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8748406
    Abstract: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: June 10, 2014
    Assignee: Medical Therapies Limited
    Inventors: Takashi Muramatsu, Kazuhiko Inoh, Hisako Muramatsu, Shuhei Torii
  • Publication number: 20120277291
    Abstract: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 1, 2012
    Applicant: Medical Therapies Ltd.
    Inventors: Takashi Muramatsu, Kazuhiko Inoh, Hisako Muramatsu, Shuhei Torii
  • Patent number: 8221758
    Abstract: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: July 17, 2012
    Assignee: Cellmid Limited
    Inventors: Takashi Muramatsu, Kazuhiko Inoh, Hisako Muramatsu, Shuhei Torii
  • Patent number: 7393672
    Abstract: A full-length cDNA is obtained by analyzing the partial amino acid sequence of purified endo-?-galactosidase C, constructing primers based thereon, effecting PCR with the use of the genomic DNA of Clostridium perfringens as a template to thereby obtain a fragment of cDNA encoding endo-?-galactosidase, effecting cassette PCR by using the cDNA fragment thus obtained to thereby obtain the 5?-terminal and 3?-terminal domains, and further effecting PCR with the use of primers constructed on the basis of the data acquired above.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: July 1, 2008
    Assignee: Seikagaku Corporation
    Inventors: Takashi Muramatsu, Haruko Ogawa, Hisako Muramatsu, Takaaki Kobayashi, Itsuo Yokoyama
  • Patent number: 7390491
    Abstract: Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or inflammatory diseases.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: June 24, 2008
    Assignee: Takashi Muramatsu
    Inventors: Tohru Takada, Kazuhiro Toriyama, Hisako Muramatsu, Takashi Muramatsu
  • Publication number: 20060177427
    Abstract: A full-length cDNA is obtained by analyzing the partial amino acid sequence of purified endo-?-galactosidase C, constructing primers based thereon, effecting PCR with the use of the genomic DNA of Clostridium perfringens as a template to thereby obtain a fragment of cDNA encoding endo-?-galactosidase, effecting cassette PCR by using the cDNA fragment thus obtained to thereby obtain the 5?-terminal and 3?-terminal domains, and further effecting PCR with the use of primers constructed on the basis of the data acquired above.
    Type: Application
    Filed: April 20, 2006
    Publication date: August 10, 2006
    Inventors: Takashi Muramatsu, Haruko Ogawa, Hisako Muramatsu, Takaaki Kobayashi, Itsuo Yokoyama
  • Publication number: 20060148738
    Abstract: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.
    Type: Application
    Filed: March 5, 2004
    Publication date: July 6, 2006
    Inventors: Takashi Muramatsu, Kazuhiko Inoh, Hisako Muramatsu, Shuhei Torii
  • Patent number: 7060483
    Abstract: A full-length cDNA is obtained by analyzing the partial amino acid sequence of purified endo-?-galactosidase C, constructing primers based thereon, effecting PCR with the use of the genomic DNA of Clostridium perfringens as a template to thereby obtain a fragment of cDNA encoding endo-?-galactosidase, effecting cassette PCR by using the cDNA fragment thus obtained to thereby obtain the 5?-terminal and 3?-terminal domains, and further effecting PCR with the use of primers constructed on the basis of the data acquired above.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: June 13, 2006
    Assignee: Seikagaku Corporation
    Inventors: Takashi Muramatsu, Haruko Ogawa, Hisako Muramatsu, Takaaki Kobayashi, Itsuo Yokoyama
  • Patent number: 6984621
    Abstract: The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1–5000 ng/ml, and more preferably 1–100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: January 10, 2006
    Assignee: Japan Tissue Engineering Co., Ltd.
    Inventors: Yukio Sumi, Kenichiro Hata, Minoru Ueda, Hisako Muramatsu, Takashi Muramatsu
  • Publication number: 20030072739
    Abstract: Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or inflammatory diseases.
    Type: Application
    Filed: November 18, 2002
    Publication date: April 17, 2003
    Inventors: Tohru Takada, Kazuhiro Toriyama, Hisako Muramatsu, Takashi Muramatsu
  • Patent number: 5629284
    Abstract: A method for treating retinal diseases includes administering an effective amount of midkine to patients suffering from retinal diseases. The method of the invention is effective in ameliorating optical disorders of retinas and is quite safe.
    Type: Grant
    Filed: July 24, 1995
    Date of Patent: May 13, 1997
    Assignee: Meiji Milk Products Co., Ltd.
    Inventors: Kazuhiko Unoki, Hitoshi Arimura, Akiko Okubo, Norio Ohba, Takashi Muramatsu, Hisako Muramatsu